GlassScriptPhysician profile
Gardith Joseph
NPI 1811928773
$9,835.96
in general payments reported to CMS, 2019-2025
54 companies · $566 in 2025
The $566 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,642 · 2020: $1,032 · 2021: $1,365 · 2022: $2,181 · 2023: $1,728 · 2024: $1,322 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,017 · Education: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,017.31 |
| Education | $598.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,074.54 | 2019-2024 | Darzalex, Tecvayli, Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $912.56 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Merck Sharp & Dohme LLC | $544.35 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $539.17 | 2019-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $491.20 | 2019-2024 | Tagrisso |
| Astellas Pharma US INC | $432.62 | 2019-2025 | Xtandi, Padcev |
| Amgen INC. | $397.36 | 2020-2023 | Lumakras |
| Novartis Pharmaceuticals Corporation | $374.21 | 2019-2025 | |
| Genzyme Corporation | $355.79 | 2019-2025 | |
| Seagen INC. | $330.68 | 2020-2023 | Adcetris |
| Celgene Corporation | $272.57 | 2019-2025 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $255.85 | 2019-2025 | Enhertu |
| Emd Serono, INC. | $223.32 | 2019-2022 | |
| Pfizer INC. | $217.02 | 2019-2024 | |
| Global Blood Therapeutics, INC. | $215.17 | 2020-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gardith Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.